Recommandations of the French Society of Photodermatology for systemic PUV atherapy in psoriasis vulgaris;Recommandations de la Societe Francaise de Photodermatologie pour la PUVAtherapie systemique dans le psoriasis vulgaire

Annales de Dermatologie et de Venereologie

Volumn 127, Issue 8-9, 2000, Pages 753-759

  Schmutz, J L ^a   Jeanmougin, M ^b   Martin, S ^a   Amblard, P ^c   Thomas, P ^a,d  

^a SERVICE DE DERMATOLOGIE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHOXSALEN;

ARTICLE; CLINICAL PROTOCOL; DOSE CALCULATION; FRANCE; HUMAN; MEDICAL INFORMATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PSORIASIS VULGARIS; PUVA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; CLINICAL TRIAL; PSORIASIS;

CLINICAL TRIALS; FRANCE; HUMANS; PSORIASIS; PUVA THERAPY;

EID: 0033797907     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Rules of evidence and clinical recommendations on the use of antithrombotic agents
2. Spectral power distribution of radiation sources used in phototherapy and photochemotherapy
3. Protection oculaire et puvatherapie
4. Ocular findings in patients treated with PUVA
5. Cutaneous and ocular side-effects of oral photochemotherapy: Results of an 8-year follow-up study
6. A retrospective study of cataract Formation in 96 patients treated with PUVA
7. Guidelines of care for phototherapy and photochemotherapy
8. British photodermatology Group guidelines for PUVA
9. Oral methoxsalen photochemotherapy for the treatement of psoriasis: A cooperative clinical trial
10. Deterioration of liver function during PUVAtherapy
11. The effect on liver transaminases of phototoxic drugs used in systemic photochemoterapy
12. Psoralen photochemotherapy
13. Interet des cinetiques plasmatiques de psoralene au cours de la Puva
14. Determination of 8-methoxypsoralen kinetics: A relevant factor in the treatement of psoriasis by psoralen plus ultraviolet A therapy
15. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatement
16. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albinos mice exposed to solar simulated irradiation
17. Treatement of psoriasis with psoralens and ultraviolet A
18. 5-Methoxypsoralen (Bregapten) for photochemotherapy
19. Le point sur la PUVAtherapie en 1994
20. 8-MOP PUVA for psoriasis: A comparison of a minimal phototoxic dose-based regimen with a skin-type approach
21. Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis
22. Response of psoriasis to twice weekly PUVA
23. A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis
24. Quand et comment arreter la puvatherapie dans le psoriasis?
25. Psoralen photochemotherapy (PUVA) and pregnancy
26. Outcomes of pregancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis
27. Effect of PUVA on immunologic and virologic findings in HIV-infected patients
28. Effect of UV-B photochemotherapy on plasma HIV type 1 RNA viral level: A self-controlled prospective study
29. Potential ocular complications from PUVA therapy and their prevention
30. UV-protective sunglasses for UVA irradiation protection
31. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation
32. Prurit et douleur cutanee induits par la puvatherapie
33. Eruptions bulleuses induites par les phototherapies
34. Celery soup causing severe phototoxicity during PUVAtherapy
35. Photo-allergie systemique au methoxalene
36. Effets secondaires de la puvatherapie
37. Antinuclear antibodies are not induced by PUVA treatement in patients with uncomplicated psoriasis
38. Nonmelanoma skin cancer occuring in patients treated with PUVA five to ten years after first treatement
39. The carcinogenic risk of treatments for severe psoriasis
40. PUVA and cancer risk: The Swedish follow-up study
41. PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of non-melanoma skin cancer
42. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA)
43. Enhanced response of psoriasis to UVB therapy after pretreatement with a lubricating base
44. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation?
45. Psoralen plus long-wave ultraviolet radiation with beta methasone valerate
46. Phototherapies et retinoides dans le traitement des psoriasis
47. Acitretin combination therapy
48. Acitretin in combination with UVB or PUVA
49. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis
50. Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study
51. Psoriasis treatment with RePUVA in the United Arab Emirates
52. Tazarotene in combination with phototherapy
53. Interactions between tazarotene and ultraviolet light
54. Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis
55. Calcipotriol improves the response of psoriasis to PUVA
56. UVB blocking effect of calcipotriene ointment 0.005 p. 100
57. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis
58. Carcinomes spinocellulaires chez cinq patients psoriasiques traites par PUVA puis par ciclosporine
59. Combined methotrexate-PUVAtherapy in the treatment of psoriasis
60. PUVA and cancer: A case-control study
61. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis